{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:18:57Z","timestamp":1790684337871,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tenofovir alafenamide (<jats:styled-content style=\"fixed-case\">TAF<\/jats:styled-content>) is a novel prodrug that reduces tenofovir plasma levels by 90% compared to tenofovir disoproxil fumarate (<jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content>), resulting in decreased bone mineral density (<jats:styled-content style=\"fixed-case\">BMD<\/jats:styled-content>) loss and renal toxicity. We aimed to study changes in <jats:styled-content style=\"fixed-case\">BMD<\/jats:styled-content> and markers of renal function of chronic hepatitis B (<jats:styled-content style=\"fixed-case\">CHB<\/jats:styled-content>) patients previously treated with <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> who were switched to <jats:styled-content style=\"fixed-case\">TAF<\/jats:styled-content> in as early as 12\u00a0weeks. This was a prospective single\u2010arm open\u2010label study of 75 <jats:styled-content style=\"fixed-case\">CHB<\/jats:styled-content> patients treated with <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> 300\u00a0mg daily who were switched to <jats:styled-content style=\"fixed-case\">TAF<\/jats:styled-content> 25\u00a0mg daily and followed for 24\u00a0weeks. All patients had been treated with <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> for at least 12\u00a0months and had <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> &lt;21\u00a0IU\/mL at the time of switch. <jats:styled-content style=\"fixed-case\">BMD<\/jats:styled-content> and markers of renal function were taken on the day of switch and repeated after 12 and 24\u00a0weeks of <jats:styled-content style=\"fixed-case\">TAF<\/jats:styled-content> treatment. Hip and spine bone mineral density significantly increased from baseline to week 12 (+12.9% and +2.4%, respectively, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01). There were significant decreases in urinary beta\u20102\u2010microglobulin to creatinine and retinol\u2010binding protein to creatinine ratios by week 12 (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01 for both). Mean estimated glomerular filtration rate (GFR) did not change. Tubular reabsorption of phosphate was decreased at week 24 (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). In conclusion, <jats:styled-content style=\"fixed-case\">CHB<\/jats:styled-content> patients previously treated with <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> experienced significant improvement in bone density and some markers of renal tubular function and as early as 12\u00a0weeks after switching to <jats:styled-content style=\"fixed-case\">TAF<\/jats:styled-content>. Bone density changes associated with <jats:styled-content style=\"fixed-case\">TDF<\/jats:styled-content> may not be entirely related to renal handling of phosphate.<\/jats:p>","DOI":"10.1111\/jvh.13053","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T22:31:16Z","timestamp":1545431476000},"page":"561-567","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9020-4880","authenticated-orcid":false,"given":"Tse\u2010Ling","family":"Fong","sequence":"first","affiliation":[{"name":"Asian Pacific Liver Center at Saint Vincent Medical Center University of Southern California  Los Angeles California"},{"name":"Division of Gastrointestinal and Liver Diseases Keck School of Medicine University of Southern California  Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal and Liver Diseases Keck School of Medicine University of Southern California  Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Tien","sequence":"additional","affiliation":[{"name":"Asian Pacific Liver Center at Saint Vincent Medical Center University of Southern California  Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Chang","sequence":"additional","affiliation":[{"name":"Asian Pacific Liver Center at Saint Vincent Medical Center University of Southern California  Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Lim","sequence":"additional","affiliation":[{"name":"Asian Pacific Liver Center at Saint Vincent Medical Center University of Southern California  Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiden","family":"Ahn","sequence":"additional","affiliation":[{"name":"Asian Pacific Liver Center at Saint Vincent Medical Center University of Southern California  Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho S.","family":"Bae","sequence":"additional","affiliation":[{"name":"Asian Pacific Liver Center at Saint Vincent Medical Center University of Southern California  Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_8_5_1","first-page":"59","article-title":"Renal and bone toxicity with the use of\u00a0tenofovir: understanding at the end","volume":"18","author":"Casado JL","year":"2016","journal-title":"AIDS Rev"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.01.022"},{"key":"e_1_2_8_7_1","first-page":"354908","article-title":"Tenofovir nephrotoxicity: 2011 update","volume":"2011","author":"Fernandez\u2010Fernandez B","year":"2011","journal-title":"AIDS Res Treat"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038377"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.07.012"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3363-4"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000569"},{"key":"e_1_2_8_12_1","first-page":"678A","article-title":"Incidence and clinical consequences of reduced tubular phosphate reabsorption in na\u00efve chronic hepatitis B patients either untreated or treated with tenofovir for 2\u00a0years in a field practice study","volume":"58","author":"Vigano M","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05093.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2649"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.09.016"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27730"},{"key":"e_1_2_8_17_1","first-page":"512","article-title":"Fanconi syndrome and chronic renal failure in a chronic hepatitis B monoinfected patient treated with tenofovir","volume":"107","author":"Magalh\u00e3es\u2010Costa P","year":"2015","journal-title":"Rev Esp Enferm Dig"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00181-2"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023688"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu471"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002276"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.035"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30107-8"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30024-3"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000908"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12123"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3000"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000248"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.08.020"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0180"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.02.080"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.26696"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12073"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.13053","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13053","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13053","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T18:56:28Z","timestamp":1694372188000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/jvh.13053"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13053","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,16]]},"assertion":[{"value":"2018-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}